Journey Medical Corp (DERM)
NASDAQ:DERM
Earnings Data
Report Date
May 19, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.08Last Year’s EPS
-0.18Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a largely positive operational and commercial narrative driven by the successful launch of Emrosi—strong prescription growth, clinical validation (JAMA Dermatology publication and superiority vs Oracea), improved gross margins, a healthier balance sheet and the achievement of positive adjusted EBITDA. Key near-term risks remain: reliance on payer/formulary timing (yielding demand-to-revenue lag), variability in revenue per script driven by reimbursement mix and co-pay program usage, pressure on legacy products from generics, and planned incremental sales/SG&A spend. On balance, progress toward sustainable profitability and multiple tangible market-access and clinical milestones outweighed the challenges discussed.Company Guidance
Successful Commercial Launch of Emrosi
Emrosi achieved $14.7 million in net sales during the 3 quarters it was commercially available in 2025; ~53,000 total prescriptions since promotion began in April 2025; Q4 prescription volume grew nearly 50% sequentially vs Q3; Q4 run-rate annualizes to over 126,000 prescriptions; unique prescribers grew from ~3,200 at year-end 2025 to over 3,500 currently (≈+9.4%).
Revenue Growth
Total revenues were $61.9 million for 2025, up 10% versus $56.1 million in 2024, driven primarily by Emrosi launch uptake.
Improved Margins
Gross margin expanded to 66.2% in 2025 from 62.8% in 2024, an improvement of ~3.4 percentage points, reflecting a more favorable product mix (Emrosi and QBREXZA) and lower inventory period costs.
Progress Toward Profitability
Adjusted EBITDA turned positive at $2.9 million in 2025 (from $0.8 million in 2024), an absolute improvement of $2.1 million; EBITDA improved by $5.2 million, narrowing the loss from $9.2 million in 2024 to a $4.0 million loss in 2025; company reported positive EBITDA and positive adjusted EBITDA in Q4 2025.
Stronger Balance Sheet and Working Capital
Cash at year-end was $24.1 million versus $20.3 million at 12/31/2024 (increase of $3.8 million, ≈+18.7%); working capital improved to $29.4 million from $13.0 million (increase of $16.4 million).
Clinical and Third-Party Validation
Emrosi's Phase III superiority data vs Oracea were published in JAMA Dermatology; the National Rosacea Society updated treatment algorithms recognizing Emrosi; management expects 2–3 additional publications in 2026—these third-party validations support payer and prescriber adoption.
Market Access Momentum
Approximately 100 million commercial covered lives currently have access to Emrosi via contracting with 2 of the top 3 GPOs; management expects the third major GPO imminently, expanding framework access toward ~150 million lives and supporting improved reimbursement and reduced reliance on co-pay assistance.
Improving Patient Retention Metrics
Refill behavior strengthened: refill ratio increased from ~1.0 refills per new prescription (Q3) to ~1.4 refills per new prescription (Q4), indicating improving patient satisfaction and potential for higher lifetime value per patient.
Planned Portfolio Expansion
Company plans to launch 1–2 incremental niche dermatology products in 2026 leveraging the existing dermatology commercial infrastructure, potentially augmenting base business revenue.
DERM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DERM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 25, 2026 | $6.83 | $4.78 | -30.01% |
Nov 12, 2025 | $9.08 | $7.69 | -15.31% |
Aug 12, 2025 | $8.54 | $7.25 | -15.11% |
May 14, 2025 | $5.97 | $7.10 | +18.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Journey Medical Corp (DERM) report earnings?
Journey Medical Corp (DERM) is schdueled to report earning on May 19, 2026, Before Open (Confirmed).
What is Journey Medical Corp (DERM) earnings time?
Journey Medical Corp (DERM) earnings time is at May 19, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DERM EPS forecast?
DERM EPS forecast for the fiscal quarter 2026 (Q1) is -0.08.